
20th Annual Congress
COLLABORATION
GLOBAL LEARNING OBJECTIVES
By the end of this event, participants will be able to:
-
Evaluate evidence-based treatment options for brain metastases in patients with gynecologic cancer and select appropriate strategies for individual cases.
-
Explain the implementation of HPV testing and self-screening protocols for cervical cancer prevention in clinical practice, in alignment with updated guidelines.
-
Apply principles of just culture and burnout prevention strategies to enhance resilience and improve workplace well-being.
-
Integrate sentinel lymph node biopsy into the management of endometrial cancer and interpret the implications of isolated tumor cells for adjuvant treatment decisions.
-
Manage endometrial intraepithelial neoplasia using current diagnostic criteria and treatment options based on recent research.
-
Describe the mechanisms, indications, and side effects of antibody-drug conjugates in gynecologic oncology and assess their clinical utility.
-
Evaluate the role of radiotherapy in the treatment of gynecologic sarcomas and justify its use based on tumor characteristics.
-
Address sexual health challenges in gynecologic cancer survivors and recommend evidence-based interventions to improve intimacy.
-
Summarize key findings from 2024–2025 publications on ovarian, endometrial, and cervical neoplasms and discuss their implications for clinical practice.
These learning objectives align with the CanMEDS framework and promote the development of competencies such as medical expertise, communication, collaboration, and professionalism.

The congress program is subject to minor modifications at the discretion of the scientific committee.
SATURDAY, NOVEMBER 22, 2025
7:50AM-8:00AM
Official opening of the congress
Dr. Laurence Bernard and Dr. Léonie Dallaire-Nantel
8H00-8H45
Folate, TROP2, HER2: Target Practice in Oncology
New developments in Antibody-drug conjugates (ADCs)
Learning objectives
At the end of this presentation, participants will be able to:
-
Describe recent advancements in antibody-drug conjugates (ADCs).
-
Discuss mechanisms of action, emerging clinical indications, and challenges related to the use of ADCs in cancer treatment.
Dr Robert Coleman
Vaniam Group
8H45-9H00
Questions and Answers
9H00-9H30
Sexual health in gyneoncology
Learning Objectives
At the end of this presentation, participants will be able to:
-
Identify common sexual health concerns experienced by patients with gynecologic cancers, including physical, emotional, and psychosocial aspects.
-
Recognize the barriers that both patients and clinicians face in discussing and addressing sexual health in gynecologic oncology settings.
-
Integrate sexual health assessment into routine cancer care and survivorship planning, using tools such as the PLISSIT model or brief screening questions.
-
Describe evidence-based interventions and referral options for managing sexual dysfunction in gynecologic cancer survivors.
Ms. Gabriella Michetti
Nurse practitioner, McGill University Health Centre (MUHC)
9H30-9H40
Questions et réponses
9H40-10H25
Precision oncology and a Patient first Pragmatic approach
Learning Objectives
At the end of this presentation, participants will be able to:
-
Recognize the emerging role for pragmatic trials in precision oncology care.
-
Describe how the value of a patient first approach can be measured in the context of a pragmatic trial.
-
Understand how a patient decision aid can help clinicians put patients first in terms of treatment decisions.
Dr Laura Hopkins, University of Saskatchewan
10H25-10H40
Questions and Answers
10:40AM-11:10AM
Break and networking with exhibitors
11:10AM-11:30AM
Ovarian neoplasia highlights
Learning Objectives
At the end of this presentation, participants will be able to:
-
Describe recent advances in the screening and diagnosis of ovarian neoplasia including the use of biomarkers and modern imaging techniques.
-
Evaluate the efficacy of systemic treatments, such as PARP inhibitors and immunotherapy, in the management of advanced or recurrent ovarian cancer.
-
Apply evidence-based recommendations from the NCCN 2024 guidelines to develop personalized treatment strategies for patients with ovarian neoplasia.
Dr. Hisham Makki
Université Laval
11:30AM-11:40AM
Questions and Answers
11H40-12H00
Highlights on Cervical Neoplasia: What’s New?
Learning objectives
At the end of this presentation, participants will be able to:
-
Summarize the key findings from 2024–2025 publications on cervical neoplasia.
-
Integrate and critically contextualize the most recent clinical recommendations for practice.
-
Evaluate future directions in research and clinical practice.
Dr Basile Pache
Université de Montréal
12H00-12H10
Questions and Answers
12:10PM-12:30PM
Endometrial Neoplasia Highlights: Navigating recent advances and controversies.
Learning Objectives
At the end of this presentation, participants will be able to:
-
Summarize the key molecular classifications of endometrial cancer and their potential impact on treatment decisions.
-
Discuss the current evidence and controversies surrounding treatment strategies within specific molecular subgroups of endometrial cancer.
-
Explore future directions in endometrial cancer research, including upcoming studies and emerging therapeutic targets.
Dr. Tomer Bar Noy
McGill University
12:30PM-12:40PM
Questions and Answers
12:40PM-13:00PM
Ovarian Cancer Canada partner update
Ms. Rehnuma Kamal
Ovarian Cancer Canada
13:00PM
Adjournment for the day
6:00PM
Cocktail
Le Parlementaire
7:00PM
Dinner
Le Parlementaire
SUNDAY, NOVEMBER 23, 2025
8H00-8H30
Reducing inequities in screening access: feasibility of HPV self-sampling in Québec
Learning Objectives
At the end of this presentation, participants will be able to:
-
Describe the preliminary findings regarding:
-
sample adequacy,
-
kit return rates,
-
HPV positivity according to risk factors.
-
-
Explore patients’ perceptions of self-sampling.
-
Discuss the essential conditions for safe and effective provincial implementation.
Dr Jessica Ruel Laliberté
8H30-8H40
Questions et réponses
8:40AM-9:10AM
Why clinical trials fail
Learning Objectives
At the end of this presentation, participants will be able to:
-
Identify the most common scientific, operational, and regulatory factors leading to clinical trial failure.
-
Analyze strategies to mitigate risks and optimize the design and implementation of future trials.
Dr. Robert Coleman
Vaniam Group
9:10AM-9:20AM
Questions and Answers
9:20AM-9:50AM
Intra-arterial chemotherapy in the treatment of brain metastases: A simple solution to overcome the blood-brain barrier
Learning Objectives
At the end of this presentation, participants will be able to:
-
Understand the physiology of the blood-brain barrier and the limitations it imposes on the effective distribution of therapeutic agents.
-
Recognize the value of intra-arterial chemotherapy in the treatment of metastatic disease, with a particular focus on ovarian cancer.
Dr David Fortin
9:50AM-10:00AM
Questions and Answers
10:00AM-10:30AM
Break and networking with exhibitors
10:30AM-11:00AM
Just Culture in Medicine and Burnout Prevention
Learning Objectives
At the end of this presentation, participants will be able to:
-
Explain the foundations and principles of a Just Culture;
-
Application of a Just Culture in medicine: patient safety, work climate, and organizational growth;
-
Use Just Culture as a tool for resilience.
Dr. Marianne Archambeault
11:00AM-11:10AM
Questions and Answers
11:10AM - 11:40AM
-
Management of endometrioid intraepithelial neoplasia (EIN)
Learning Objectives
At the end of this presentation, participants will be able to:
-
Apply histopathological and molecular criteria to improve the diagnosis of EIN.
-
Select the optimal conservative or definitive treatment based on the patient's risk profile.
-
Implement individualized monitoring that incorporates metabolic, genetic, and lifestyle factors.
Dr. Marie-Hélène Auclair
-
Management of Endometrial Hyperplasia with Atypia
Learning Objectives
At the end of this presentation, participants will be able to:
-
Identify the diagnostic criteria and risk factors associated with endometrial hyperplasias with atypia.
-
Describe the therapeutic management and follow-up options for patients presenting with endometrial hyperplasia with atypia.
Dr. Omar Touhami
11:40AM-11:50AM
Questions and Answers
11:50AM
Adjournment for the day
SPEAKERS
ROBERT L. COLEMAN, MD, FACOG, FACS
Chief Medical Officer
Vaniam Group
Dr. Coleman completed his Obstetrics & Gynecology residency at Northwestern University Medical Center in Chicago, Illinois, and completed his fellowship at The University of Texas MD Anderson Cancer Center in 1993. From 1993-1996, he served as Assistant Professor at Creighton University followed by service as Vice-Chairman, Department of Obstetrics and Gynecology at the University of Texas, Southwestern Medical Center. Dr. Coleman joined as Faculty at MD Anderson Cancer center in 2004 and served as Professor and Executive Director for Cancer Network Research, holding the Ann Rife Cox Chair in Gynecology. In March 2020, he joined US Oncology Research (USOR) as Chief Scientific Officer and served briefly as Chief Medical Officer for Sarah Cannon Research Institute (SCRI). He practices at Texas Oncology, US Oncology Network and currently serves as Chief Medical officer for Vaniam Group. He also serves as Vice President, GOG Foundation and is Special Advisor to the President for GOG Partners. Dr. Coleman has authored or coauthored over 800 scientific publications, including over 470 peer-reviewed articles, along with numerous book chapters, monographs, invited articles, and textbooks. He was the 2019 APGO-CREOG awardee for Excellence in Teaching. He served as President of SGO (2015-2016) and President of IGCS (2020-2022). He was recently inducted into MJH Life Sciences™ 2020 class of “Giants in Cancer Care®.”

MARIE-HÉLÈNE AUCLAIR, MDCM, FRCSC, dABOM, Mschq
Gynécologue Oncologue
CIUSSS de l'Est de l'Île De Montréal
Dr. Auclair is a specialist in gynecologic oncology and an assistant clinical professor at the CIUSSS de l'Est-de-l'île-de-Montréal. She obtained her MD from McGill University in Montreal in 2010, her residency in obstetrics and gynecology also at McGill University in 2016, and her subspecialty in gynecologic oncology at the Université de Montréal in 2019. Dr. Auclair completed her American Board of Obesity Medicine in 2021 and subsequently founded a survivorship clinic for patients followed by her team at Maisonneuve-Rosemont Hospital. Dr. Auclair completed her Master's degree in Healthcare Quality at QUEEN's University in Kingston in 2023. She represents her department on the Maisonneuve-Rosemont Hospital's Central Committee for the Evaluation of Medical, Dental, and Pharmaceutical Procedures. She has also contributed to scientific articles, a book chapter, and clinical guidelines, including the SOGC clinical guideline "Classification and Management of Endometrial Hyperplasia" and the joint guideline of the Canadian Society of Gynecologic Oncology (GOC), the Canadian Colposcopy Society (CCS), and the Canadian Partnership Against Cancer (CPAC) "Canadian Colposcopy Guidelines: A Risk-Based Approach to the Management and Surveillance of Cervical Dysplasia, 2023." Her clinical interests include survivorship, medical management of obesity, and early recovery.

DAVID FORTIN, M.D
Full Professor
Université de Sherbrooke
Dr. David Fortin is a neurosurgeon, neuro-oncologist, and full professor at the Faculty of Medicine and Health Sciences of the Université de Sherbrooke. He founded and directs the Brain Tumor Research Laboratory and has over 160 publications and 180 scientific abstracts to his credit. After completing his medical studies and neurosurgery training, he pursued further training in neuro-oncology at Western University and then at Oregon Health Sciences University. He has received numerous distinctions, including the César Galéano Award for Best Professor in the Faculty of Medicine from 2005 to 2010, and the Research Outreach Award from the Clinical Research Centre of the CHUS in 2010. In 2018, he was named Quebec Specialist Physician of the Year by the Royal College of Physicians and Surgeons of Canada. In 2025, he received the Award of Excellence from the Collège des médecins du Québec. His fourth book was published and has been available in bookstores since April 2025: Allumé! Advice from a Neurosurgeon on Keeping Your Brain Healthy! A fifth book is expected in 2026. He is also active in the media, having been a columnist for the program Pénélope on Radio-Canada and Salut Bonjour on TVA.

OMAR TOUHAMI,
Head of Department – Gynecologic Oncology
Charles-Le Moyne Hospital.
Gynecologic Oncologist – Charles-Le Moyne Hospital. Treasurer – Regroupement des Gynécologues Oncologues du Québec (RGOQ). Representative – Canadian Cancer Trials Group (CCTG). Clinical Professor – Université de Sherbrooke.

LAURA HOPKINS,
Gynecologic Oncologist
University of Saskatchewan
Laura Hopkins is a Professor in the Department of Oncology and a Gynecologic Oncologist with the Saskatchewan Cancer Agency. Laura completed her Fellowship in Gynecologic Oncology at the University of Toronto in 2002 and worked in Ottawa until 2019. She moved to Saskatoon in 2019 and established an academic program for patients with gynecologic cancer. The path to an academic focus began with opening Saskatchewan’s first tumor bank in 2021, which allowed Saskatchewan to become part of the Terry Fox Marathon of Hope Cancer Network. The first clinical trial in gynecologic oncology was activated in 2021. A robotic surgery program was launched in 2022. Laura leads the Saskatchewan Cancer Agency’s first investigator-initiated clinical pragmatic trial which explores patient’s preferences for precision medicine in ovarian cancer. This trial was activated in 2023 and leverages the cooperation of patients, oncologists, pathologists and basic scientists in order to improve patient quality of life, promote informed patient decision making. Preliminary results of this trial have been used to justify a new precision standard of care for patients with ovarian cancer in Saskatchewan.

TOMER BAR NOY,
Fellow
McGill University
Dr. Tomer Bar-Noy is currently a Gyneoncology fellow at McGill University in Montreal. He received his Medical Doctorate from Tel-Aviv University, Israel. Dr. Bar-Noy completed his residency in Obstetrics and Gynecology at the Technion Institute in Israel and subsequently worked as a senior doctor in the Gyne-oncological unit at Hillel Yaffe Medical Centre. His latest translational study focuses on MMRp endometrial cancer at the Lady Davis Institute for Medical Research at the Jewish General Hospital in Montreal.

GABRIELLA MICHETTI, RN, MScA, IPSSA
Nurse Practitioner
McGill University Health Centre (MUHC)
Gabriella is a Nurse Practitioner specialized in gynecologic oncology with over 12 years of experience caring for women affected by gynecologic cancers. She holds a Master’s degree in Advanced Nursing Practice and is certificate as a nurse practitioner in adult care. Her clinical work is grounded in a deep commitment to comprehensive, compassionate care for women navigating complex diagnoses. With a strong interest in women’s health and survivorship, Gabriella has developed a particular passion for addressing sexual health—an often overlooked but essential component of quality of life in oncology care. She is currently leading efforts to develop a dedicated sexual health clinic tailored specifically for patients in the gynecologic oncology population.

JESSICA RUEL-LALIBERTÉ, MD, Msc
Gynecologist Oncologist
CIUSSS of Estrie - CHUS
Dr. Jessica Ruel-Laliberté is a gynecologic oncologist and Assistant Professor at the University of Sherbrooke. She is dedicated to improving screening and management of gynecological cancers. Her current research project aims to evaluate the feasibility of a large-scale HPV self-sampling program in Quebec, an approach that could transform access to cervical cancer screening.

HISHAM MAKKI,
Fellow in Gynecologic Oncology
CHU de Québec, Université Laval
Dr. Hisham Makki is currently a fellow in gynecologic oncology at Laval University in Quebec. He completed his residency in obstetrics and gynecology at the University of Montreal. He is a graduate of the Royal College of Surgeons in Ireland. His current clinical and academic interests focus on advanced systemic therapies in gynecologic cancers.

MARIE-ANNE ARCHAMBAULT-GRENIER,
Hematologist-oncologist
Pierre LeGardeur Hospital
Graduate of a Bachelor’s degree in Psychology from UQAM, Dr. Marie-Anne Archambault pursued her medical studies at the Université de Montréal, where she completed specialties in Internal Medicine, Hematology, and Oncology. She has been practicing at CISSS Sud de Lanaudière, Hôpital Pierre-Le Gardeur since 2010. Dr. Archambault is passionate about Continuing Professional Development (CPD), equity, diversity and inclusion (EDI), Just Culture, cultural safety, end-of-life care, and the psychological journey of patients and their loved ones. A member of the CPD Committee of the Association des médecins hématologues et oncologues du Québec (AMHOQ) since 2021, she is also an associate member of the Sexual and Gender Diversity in Cancer Care initiative, the PMChosenFamily project with Princess Margaret Hospital in Toronto.

BASILE PACHE
Clinical Fellow
Centre hospitalier de l'Université de Montréal
Dr. Basile Pache completed his training in obstetrics and gynecology at the University Hospital of Lausanne, before continuing at the Hospices Civils de Lyon in gynecologic oncology. He has now joined the CHUM as a clinical fellow. His main interests in oncology focus on peritoneal carcinomatosis and its surgical treatments.

Venues
Join us for the 20th Annual Congress, which will take place in the Multi-Purpose Hall of the CHU de Québec – Université Laval, located at 2260 Boul. Henri-Bourassa, Québec (Québec) G1J 5B3.
To conclude the congress, we invite you to a celebratory dinner at Le Parlementaire restaurant, a unique venue that showcases the flavors of Québec. Featuring a menu crafted with local ingredients from various regions, this elegant establishment offers a refined dining experience in the historic setting of the National Assembly of Québec.
We look forward to celebrating this special occasion with you!

Delta Québec
We've secured discounted rates at the Delta Quebec, with a limited number of rooms available at these exclusive prices. Rooms are available on a first-come, first-served basis, so we strongly encourage you to book as soon as possible to take advantage of the best selection and rates. The discounted rate is available until September 18 at 11:59 PM ET, or until the room block is full, whichever comes first.
Ideally located in the heart of the city, the Delta Québec is just a 4-minute walk from the venue for the annual congress dinner, Restaurant Le Parlementaire (1045 Rue des Parlementaires, Québec, QC G1A 1A3) , and just an 8-minute drive from the main congress venue, Salle Polyvalente du CHU de Québec – Université Laval (2260, boulevard Henri-Bourassa, Québec, QC G1J 5B3).


Scientific Committee
Partners
This content was developed by the RGOQ with unrestricted funding from the following partners.
-
DIAMOND PLUS: Merck Canada
-
PLATINUM: AbbVie
-
GOLD: AstraZeneca, GSK
-
SILVER: Eisai
-
BRONZE: CONMED, Olympus
The partners played no role in the development of the content, the selection of topics, or the selection of speakers. The opinions expressed in this presentation are solely those of the authors/speakers.
Become Our Partner
RGOQ is the partner of choice for healthcare organizations, hospitals, patient advocacy groups, pharmaceutical companies, and medical device manufacturers that share our vision and commitment. By partnering with us, you join a network of professionals and organizations dedicated to improving patient outcomes and advancing the field of gynecologic oncology.




.png)
